9 June 2022
DEMECAN expands and diversifies its network of international suppliers of cannabis

DEMECAN has signed major supply agreements for medicinal cannabis flowers with Little Green Pharma (Denmark), Safricanna (South Africa), and Atlas Growers (Canada). Over the next few years, DEMECAN will be supplied exclusively with at least 6 different medical cannabis flowers from these three suppliers. Deliveries will begin this year, subject to regulatory and licensing requirements. The combined amount will be over 2.2 tons of dried cannabis flower in the first year of delivery alone. […]

11 May 2022
DEMECAN launches medicinal cannabis flower with cultivar Sour Kush

DEMECAN, the only independent German producer of medicinal cannabis, is celebrating the launch of its supply agreement with Northern Green Canada with the launch of its new indica-dominant medicinal cannabis flower. With the expansion of the product portfolio, DEMECAN is helping to further improve patient care in Germany and is further expanding its position in the German cannabis market. […]

20 April 2022
DEMECAN delivers first medical cannabis from its own German facility

DEMECAN, the only independent German producer of medical cannabis, has made the first cannabis flowers available for collection by the German Federal Institute for Drugs and Medical Devices (BfArM). With this, DEMECAN ensures a constant supply of high-quality medical cannabis from German cultivation and increases the independence from imports in the supply of medicinal products. […]

9 March 2022
Growth Opportunity Cannabis Legalization

DEMECAN founder Dr. Maurer joins the supervisory board and hands over operational responsibility to former Merck manager Dr. Goebel DEMECAN founder Dr. Cornelius Maurer joins the supervisory board of DEMECAN and will focus on the strategic topics such as legalization of cannabis for recreational purposes, German cannabis association work and fundraising. Dr. Cornelius Maurer hands […]

25 January 2022
DEMECAN receives GMP certificate for cannabis production facility

DEMECAN, the only independent German producer of medicinal cannabis, has been granted a manufacturing license in accordance with §13 AMG (German Medicines Act) and GMP (Good Manufacturing Practice) certification for its production facility near Dresden. The GMP manufacturing license granted by the Saxon state authority allows DEMECAN to produce dried cannabis as medicinal products with immediate effect. […]

15 September 2021
DEMECAN receives state subsidies and strengthens its management with Jörg Sellmann

DEMECAN, the only independent German producer of medical cannabis, will receive substantial state subsidies worth several million Euros. An application for the “Gemeinschaftsaufgabe ‘Verbesserung der regionalen Wirtschaftsstruktur’” (GRW) subsidies, which had been submitted to the Sächsische Aufbaubank for the expansion of the production plant near Dresden, was recently approved. . […]

15 July 2021
DEMECAN Betriebsstätte wächst, Handwerker*innen feiern Richtfest

Noch im Herbst wird DEMECAN, der einzige unabhängige deutsche Produzent von medizinischem Cannabis, mit dem Anbau beginnen. Die 100.000 m² große Fläche in Ebersbach nahe Dresden […]

16 April 2021
DEMECAN again receives funding in the millions

DEMECAN, Germany’s only independent producer of medical cannabis, has closed another multi-million Euro financing round. The investment will be used for further growth as well as the expansion of the production facility, located near Dresden, into Europe’s most modern facility for the cultivation and processing of medicinal cannabis. […]

9 March 2021
DEMECAN erhält Darlehen in einstelliger Millionenhöhe von der Volksbank Mittweida eG

DEMECAN – der einzige unabhängige deutsche Produzent von medizinischem Cannabis – erhält von der Volksbank Mittweida eine Fremdkapitalfinanzierung in Millionenhöhe. Das Darlehen dient der Finanzierung des im Sommer 2020 geglückten Erwerbs der Produktionsstätte für medizinisches Cannabis. […] (only german)

3 March 2021
DEMECAN: With pioneering spirit and responsibility for patient care.

For just under four years, seriously ill patients have been able to obtain medical cannabis on prescription. Tens of thousands of patients with chronic pain, spasticity, anorexia/wasting, nausea and vomiting during chemotherapy already benefit from this additional therapy option. […]